XTalks
DECEMBER 12, 2023
Our pipeline, for example, includes a new class of recombinant antibodies. Our product portfolio spans various stages of development, featuring innovative therapeutic options such as recombinant polyclonal antibodies soon to enter the clinic, and new oncology treatments. The science is brilliant.
Drug Discovery World
NOVEMBER 9, 2023
Lei Shi, PhD, Senior Vice President, R&D, Biointron Biological, on: ‘Accelerating early discovery through htp and high-speed antibody production’. Paul Dyer, PhD, Field Application Scientist, Halo Labs, on: ‘Total particle analysis with aura; pathway to USP validation and product release’.
The Pharma Data
JANUARY 18, 2021
From this, BT-001 is engineered to encode both a highly differentiated Treg depleting anti-CTLA4 antibody and the human GM-CSF cytokine. The recombinant antibody recognizing human CTLA4 was generated by BioInvent’s proprietary n-CoDeR®/F.I.R.S.T
Expert insights. Personalized for you.
111 
Let's personalize your content